u/kvmcc · 301d agono track record yet
$PSTV - Why I’m holding through 2026. This isn't your typical "hope and pray" biotech
Plus Therapeutics has a revenue-generating diagnostic (CNSide) with strong adoption at 120+ cancer centers and major payer coverage, plus a high-potential pipeline asset (REYOBIQ) in late-stage trials. With insiders aggressively buying and a $7.25 analyst target against a $0.55 current price, the risk-reward is asymmetric through 2026.